Identity recordFDA-approved US medicine with country-specific status elsewhere
What Orforglipron / Foundayo resolves to
FOUNDAYO is an FDA-approved US oral medicine containing the non-peptide small molecule orforglipron. That US approval does not establish authorization, launch, prescription access, market presence, supply, or seller authority in another country, and it does not authenticate a same-name research or imported product.
- Evidence lane
- FDA-approved medicine
- Current record
- NDA 220934 · FDA-approved prescription drug
- Checked
- July 20, 2026
orforglipronFoundayoLY3502970NDA 220934oral GLP-1
Destination recordPeptide-specific SAHPRA warning
What South Africa still has to prove
A South Africa guide to checking peptide offers against SAHPRA's current public warning, registered-medicine directory, and licensed-establishment records.
- Comparison mode
- ZAR / SAHPRA product and establishment records
- Price coverage
- No qualified South Africa seller table
- Guide updated
- July 18, 2026